|
16 Nov 2019 |
CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma
|
|
16 Nov 2019 |
CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
|
|
16 Nov 2019 |
Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program
|
|
16 Nov 2019 |
Recordati: CHMP adopts positive opinion for Isturisa (osilodrostat)
|
|
16 Nov 2019 |
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
|
|
16 Nov 2019 |
RemeGen, Ltd. Announces Positive Results from Phase IIb Clinical Trial in Systemic Lupus Erythematosus
|
|
16 Nov 2019 |
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
|
|
16 Nov 2019 |
Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma
|
|
16 Nov 2019 |
Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program
|
|
16 Nov 2019 |
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
|
|
16 Nov 2019 |
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
|
|
16 Nov 2019 |
Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
|
|
16 Nov 2019 |
New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
|
|
16 Nov 2019 |
Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche
|
|
15 Nov 2019 |
Qtrilmet approved in the EU for the treatment of type-2 diabetes
|
|
15 Nov 2019 |
U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy
|
|
15 Nov 2019 |
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting
|
|
15 Nov 2019 |
FETROJA® (cefiderocol) Approved by the FDA for Treatment of Complicated Urinary Tract Infections (cUTI) in Adult Patients with Limited or No Alternative Treatment Options
|
|
15 Nov 2019 |
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
|
|
14 Nov 2019 |
Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111
|
